AzTrials
AzTrials

Chronic Heart FailureGUIDE-CRTNCT03125720

Image Fusion of SPECT MPI and Fluoroscopy Venography to Guide LV Lead Placement for Improved CRT Response (GUIDE-CRT II)

A study testing Image fusion of SPECT MPI and fluoroscopy venography in people with Chronic Heart Failure, run by The First Affiliated Hospital with Nanjing Medical University at 14 sites in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

CRT response will be significantly better using image fusion of SPECT MPI and fluoroscopy venogram to guide LV lead placement at the latest activation segment without scar than standard-of-care implantation. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Chronic Heart Failure
What is being tested?
Image fusion of SPECT MPI and fluoroscopy venography
Could I receive a placebo?
No, everyone receives an active treatment
How many people
300 participants
Where
14 sitesChina
Study dates
14 Apr 2017to 31 May 2025
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Patient has signed informed consent
  • moderate to severe HF (NYHA Class II, III or IV)
  • LVEF ≤35%
  • QRS duration ≥130 ms
  • sinus rhythm

Who cannot join

  • Patient is under a minimum age requirement (<18 years old)
  • Patient has mechanical right heart valve
  • Patient has experienced unstable angina, acute MI, CABG or PCI within the past 3 months
  • Patient is on continuous or intermittent (i.e., more than two infusions per week) intravenous inotropic drug therapy
  • Patient known to have chronic permanent atrial arrhythmias (i.e., cases of long-standing atrial fibrillation of greater than 1 year, including those in which cardioversion has not been indicated or attempted).
  • Patient is enrolled in any other study
Show all 11Show fewer
  • Patient has a life expectancy of less than 12 months
  • Women who are pregnant, or with child-bearing potential and who are not on a form of birth control
  • Patient with CRT device implanted previously
  • Patient has had a heart transplant
  • Patient has third degree AVB with normal cardiac function

Trial locations and contacts

14 sites in 1 country.

14 sites in 1 country

China14 sites
  • Fu Wai Hospital

    Beijing

  • West China Hospital

    Chengdu, Sichuan

  • The First Affiliated Hospital of Dalian Medical University

    Dalian, Liaoning

  • First Affiliated Hospital,Zhejiang University

    Hangzhou, Zhejiang

  • First People's Hospital of Hangzhou

    Hangzhou, Zhejiang

  • Sir Run Run Shaw Hospital

    Hangzhou, Zhejiang

  • Anhui Provincial Hospital

    Hefei, Anhui

  • Shanghai Chest Hospital

    Shanghai

  • Zhongshan Hospital

    Shanghai

  • The General Hospital of Shenyang Military

    Shenyang, Liaoning

  • First Affiliated Hospital Xi'an Jiaotong University

    Xi'an

  • Xijing Hospital

    Xi'an

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu

  • Northern Jiangsu Province People's Hospital

    Yangzhou, Jiangsu

Other trials in China

About this study

CRT response will be significantly better using image fusion of SPECT MPI and fluoroscopy venogram to guide LV lead placement at the latest activation segment without scar than standard-of-care implantation.

Read the detailed description

Chronic heart failure (CHF) is final phase of a variety of cardiovascular diseases. Epidemiological data revealed that the morbidity of CHF is 0.9% in China, and there are 300,000 new CHF patients are diagnosed each year. Moreover, the total number of CHF patients exceeded 5.5 million throughout the country. Therefore, CHF has become a seriously social and public health problem in China.

Although medical treatment for CHF has achieved considerable progress, prognosis is still poor and mortality is high among end-stage HF patients. Since the 1990s, cardiac resynchronization therapy(CRT) has been applied to treat CHF, a large number of evidence-based medicine has shown that CRT brings great clinical effects; CRT mainly aims at delayed activation of left ventricular(LV) and stimulates LV in advance to restore the inter- and intra-ventricular synchrony. As a result, cardiac function, symptoms and quality of life in CHF patients improved, meanwhile mortality rate also decreases. At present, CRT is recommended in quite a number of CHF patients as class I indication. And yet, approximately 30%-40% of patients did not show response to CRT. Non-response to CRT has become a significant problem that must be solved. In recent years, researchers have tried LV multipoint pacing (MPP), transseptal left ventricular endocardial pacing and MitraClip to get some achievements. But these new techniques and CRT itself have two main failings:(1) Up to now, there is no specific suggestions about whether the patient's myocardium has too severe myocardial fibrosis and scar burden to be fit for CRT.(2)The LV mechanical dysynchronization will influence CRT effects. So far, screening CRT indications is primarily based on QRS morphology and duration on surface electrocardiogram.QRS duration≥120ms represents the presence of electrical dysynchronization, however, electrical dysynchronization is not equal to mechanical dysynchronization. The key point of CRT is to solve the mechanical dysynchronization, so estimating cardiac mechanical dysynchrony is important for predicting the CRT response; In addition, LV lead implantation site also exerts an effect on CRT response. The standard-of-care of LV lead implantation technique now just relays on coronary vein angiography showing the appropriate branch vein. This approach cannot guarantee LV lead is implanted in the latest activation site and the non-scar segment. Therefore, the following two issues are very important: how to evaluate the myocardiac scar and LV mechanical dyssynchronization using an objective, accurate, simple and economic method? and how to explore a new image which can guide LV lead to position at the latest activation and non-scar segment conveniently and accurately during procedure for improving CRT response rate? Myocardial perfusion image-phase analysis technique(MPI-PA) is a new non-invasive method to evaluate LV desynchronization,the latest activation site and myocardial scar burden. In recent years,Henneman MM and Adelstein EC reported PA technique detecting LV systolic desynchronization and LV scar burden influencing on CRT response respectively. Their study showed that the low CRT response is associated with the mild LV dyssynchrony and severe scar burden.The past five years,our center has completed a prospective, randomized, multi-center study of"SPECT guided LV Lead Placement for Incremental Benefits to CRT Efficacy"(GUIDE-CRT).We found that the CRT efficacy in SPECT-Guided group at 6 months after CRT implantation was better than that in standard-of-care implantation group(control group):the reduction in LVESV at 6 months in guided group is much more than that in control group(control 28.2ml vs guided group 48.2ml,P=0.029). The CRT response rate, defined as reduction in LVESV more than 15%, in guided group was 55.8% is higher than 47.8% in control group,but there was no statistic difference between two groups.The guiding mothodology of implanting LV lead in our previous study (GUIDE-CRT) was as following: implanter chose the branch vein to implant LV lead based on the recommended site by MPI-PA. Under this guidance, still much percentage of LV lead did not located in the recommended site. Therefore, in order to further improve the accuracy of SPECT guiding LV lead placement, our present study will use automatic fusion of coronary venogram with SPECT images to guide the implantation of LV lead precisely, and bringing incremental benefits to CRT efficacy.

This new study(GUIDE-CRT II) is a prospective, randomized, multi-center trial. Applying the new image fusion of SPECT MPI and coronary venogram to guide LV lead placement at the recommended optimal position, to achieve the precise localization, to avoid blindness of standard of care implantation methods and to improve response to CRT.

Being tested
Image fusion of SPECT MPI and fluoroscopy venography
Keywords
cardiac resynchronization therapy, chronic heart failure, image fusion-guided implantation, SPECT, venogram

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Image fusion of SPECT MPI and fluoroscopy venographyOther

    In this study, MPI-Fluoro Fusion tool is used to help the implanting physicians to precisely implant LV lead to the optimal/suboptimal venous segments in the guided group.

Study groups in NCT03125720
Study groupRoleWhat they receive
GUIDED groupExperimentalImage fusion of SPECT MPI and fluoroscopy venography to guide LV lead placement for improved CRT response in the guided group.
Receives: Other: Image fusion of SPECT MPI and fluoroscopy venography
Control groupNo interventionNo Image fusion of SPECT MPI and fluoroscopy venography to guide LV lead placement for improved CRT response.

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Changes in LVESV

    Changes in LVESV between baseline and 6-month follow-up (a continuous variable): LVESV will be assessed by echocardiography (Simpson's rule). Changes in LVESV will be compared between the two groups.

    Measured: 6-month follow-up

Secondary outcomes (4)
  1. CRT response rate

    The proportion of the positive CRT response in each group. A positive CRT response is defined as reduction in LVESV by ≥15% and/or LVEF increase by ≥10% at 6-month follow-up as compared to the baseline.

    Measured: 6-month follow-up

  2. Changes in LVEF

    LVEF will be assessed by echocardiography (Simpson's rule) and compared between the baseline and 6-month follow-up. Changes in LVEF will be compared between the two groups.

    Measured: 6-month follow-up

  3. Composite clinical response rate

    A positive response is defined as decrease by ≥1 NYHA class and/or improvement in 6MWD by ≥10% and/or decrease in QOL score by ≥ 9 points at 6-month follow-up.

    • NYHA class: Changes in NYHA class at 6-month follow-up as compared to the baseline will be compared between the two groups.
    • 6MWD: Changes in 6MWD at 6-month follow-up as compared to the baseline will be compared between the two groups.
    • QOL: Changes in QOL score at 6-month follow-up as compared to the baseline will be compared between the two groups.

    Measured: 6-month follow-up

  4. All-cause mortality and composite clinical endpoints

    All-cause mortality,all-cause death and heart failure re-hospitalization by the end of study.

    Measured: 6-month follow-up

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted24 Apr 2017
  2. Study start14 Apr 2017
  3. Primary completion31 Dec 2024
  4. Study completion31 May 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Care provider, Outcomes assessor
Enrolment
300 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03125720
Sponsor's protocol ID
FirstNanjingMU001
Acronym
GUIDE-CRT
Status last verified
Mar 2025
First submitted
14 Apr 2017
Last updated
17 Aug 2025
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Khan FZ, Virdee MS, Palmer CR, Pugh PJ, O'Halloran D, Elsik M, Read PA, Begley D, Fynn SP, Dutka DP. Targeted left ventricular lead placement to guide cardiac resynchronization therapy: the TARGET study: a randomized, controlled trial. J Am Coll Cardiol. 2012 Apr 24;59(17):1509-18. doi: 10.1016/j.jacc.2011.12.030. Epub 2012 Mar 7.

    PubMed 22405632
  • Zhou W, Hou X, Piccinelli M, Tang X, Tang L, Cao K, Garcia EV, Zou J, Chen J. 3D fusion of LV venous anatomy on fluoroscopy venograms with epicardial surface on SPECT myocardial perfusion images for guiding CRT LV lead placement. JACC Cardiovasc Imaging. 2014 Dec;7(12):1239-48. doi: 10.1016/j.jcmg.2014.09.002. Epub 2014 Nov 5.

    PubMed 25440593

Questions about this trial

What is this clinical trial studying?

A study testing Image fusion of SPECT MPI and fluoroscopy venography in people with Chronic Heart Failure, run by The First Affiliated Hospital with Nanjing Medical University at 14 sites in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 11 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 17 Aug 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 14 sites in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Changes in LVESV (time frame: 6-month follow-up). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03125720, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Aug 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in